Publications

   

2024

  
   
62. Validation of putative biomarkers of furan exposure through quantitative analysis of furan metabolites in urine of F344 rats exposed to stable isotope labeled furan.
Kalisch C, Reiter M, Krieger M, Wüst L, Klotz C, Dekant R, Lachenmeier DW, Scherf-Clavel O, Mally A.
Arch Toxicol. 2024 Jun;98(6):1741-1756. doi: 10.1007/s00204-024-03722-5.
61. Targeted and untargeted screening for impurities in losartan tablets marketed in Germany by means of liquid chromatography/high resolution mass spectrometry.
Backer L, Kinzig M, Sörgel F, Scherf-Clavel O, Holzgrabe U.
J Pharm Biomed Anal. 2024 Aug 1;245:116160. doi: 10.1016/j.jpba.2024.116160.
60. Application of advanced high resolution mass spectrometric techniques for the analysis of losartan potassium regarding known and unknown impurities.
Backer L, Buschmann H, Kinzig M, Sörgel F, Scherf-Clavel O, Holzgrabe U.
J Pharm Biomed Anal. 2024 Mar 15;240:115955. doi: 10.1016/j.jpba.2023.115955.
59. Understanding adefovir pharmacokinetics as a component of a transporter phenotyping cocktail.
Dong Q, Chen C, Taubert M, Bilal M, Kinzig M, Sörgel F, Scherf-Clavel O, Fuhr U, Dokos C.
Eur J Clin Pharmacol. 2024 Jul;80(7):1069-1078. doi: 10.1007/s00228-024-03673-x.
58. Prediction of Degradation Profiles for Various Sartans under Solvent-Free Mechanochemical Conditions.
Amer MM, Backer L, Buschmann H, Handler N, Scherf-Clavel O, Holzgrabe U, Bolm C.
Anal Chem. 2024 Aug 13;96(32):13166-13173. doi: 10.1021/acs.analchem.4c02025.
57. Investigation of clindamycin concentrations in human plasma and jawbone tissue in patients with osteonecrosis of the jaw: A prospective trial.
Straub A, Stapf M, Brands RC, Kübler AC, Lâm TT, Vollmer A, Gubik S, Scherf-Clavel O, Hartmann S.
J Craniomaxillofac Surg. 2024 Mar;52(3):355-362. doi: 10.1016/j.jcms.2024.01.014.
56. Antimicrobial effects of clindamycin-loaded platelet-rich fibrin (PRF).
Straub A, Stapf M, Utz C, Vollmer A, Flesch J, Kübler A, Scherf-Clavel O, Lâm TT, Hartmann S.
Clin Oral Investig. 2024 Feb 13;28(2):144. doi: 10.1007/s00784-024-05532-6
   

2023

  
   
55. Identification of low-level impurities in drug prototypes of carbocisteine by means of liquid chromatography-high-resolution mass spectrometry and general unknown comparative screening.
Walther R, Kinzig M, Zamponi A, Sörgel F, Scherf-Clavel O, Holzgrabe U.
J Chromatogr A. 2023 Sep 13;1706:464269. doi: 10.1016/j.chroma.2023.464269
54. Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib.
Zimmermann S, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Gesierich A, Schilling B, Kalogirou C, Goebeler ME, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O.
J Pharm Biomed Anal. 2023 May 10;228:115311. doi: 10.1016/j.jpba.2023.115311
53. Present in the Aquatic Environment, Unclear Evidence in Top Predators-The Unknown Effects of Anti-Seizure Medication on Eurasian Otters (Lutra lutra) from Northern Germany.
Rohner S, Gramer M, Wiesweg I, Scherf-Clavel O, Wohlsein P, Schmelz M, Siebert U, Richter F, Gernert M.
Toxics. 2023 Mar 31;11(4):338. doi: 10.3390/toxics11040338.
52. The solvent- and surface-dependent adsorption of the lipopeptide antibiotic daptomycin: The general necessity of adsorption tests.
Kirchner L, Marciniak T, Ziebuhr W, Scherf-Clavel O, Holzgrabe U.
J Pharm Biomed Anal. 2023 Oct 25;235:115657. doi: 10.1016/j.jpba.2023.115657
51. Development, validation and application of a selective and sensitive LC-MS/MS method for the quantification of daptomycin in a suspension of Mammaliicoccus sciuri in Mueller-Hinton broth.
Kirchner L, Marciniak T, Ziebuhr W, Scherf-Clavel O, Holzgrabe U.
J Pharm Biomed Anal. 2023 Apr 1;227:115293. doi: 10.1016/j.jpba.2023.115293
50. Bile Is a Selective Elevator for Mucosal Mechanics and Transport.
Hanio S, Möllmert S, Möckel C, Choudhury S, Höpfel AI, Zorn T, Endres S, Schlauersbach J, Scheller L, Keßler C, Scherf-Clavel O, Bellstedt P, Schubert US, Pöppler AC, Heinze KG, Guck J, Meinel L.
Mol Pharm. 2023 Dec 4;20(12):6151-6161. doi: 10.1021/acs.molpharmaceut.3c00550
49. Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1.
Zhou X, Han S, Cebulla N, Haertle L, Steinhardt MJ, Schirmer D, Runau E, Flamm L, Terhorst C, Jähnel L, Vogt C, Nerreter S, Teufel E, Stanojkovska E, Mersi J, Munawar U, Schindehütte M, Blum R, Reinhold AK, Scherf-Clavel O, Rittner HL, Pham M, Rasche L, Einsele H, Sommer C, Kortüm KM.
Biomark Res. 2023 May 16;11(1):52. doi: 10.1186/s40364-023-00490-9.
48. Harnessing Bile for Drug Absorption through Rational Excipient Selection.
Schlauersbach J, Werthmüller D, Harlacher C, Galli B, Hanio S, Lenz B, Endres S, Pöppler AC, Scherf-Clavel O, Meinel L.
Mol Pharm. 2023 Aug 7;20(8):3864-3875. doi: 10.1021/acs.molpharmaceut.2c01009.
47. A liquid chromatography-tandem mass spectrometry method for the quantification of ampicillin/sulbactam and clindamycin in jawbone, plasma, and platelet-rich fibrin: Application to patients with osteonecrosis of the jaw.
Stapf M, Straub A, Fischer M, Linz C, Hartmann S, Scherf-Clavel O.
J Pharm Biomed Anal. 2023 Feb 5;224:115167. doi: 10.1016/j.jpba.2022.115167
46. Oral Use of Therapeutic Carbon Monoxide for Anyone, Anywhere, and Anytime.Reiländer S, Schmehl W, Popp K, Nuss K, Kronen P, Verdino D, Wiezorek C, Gutmann M, Hahn L, Däubler C, Meining A, Raschig M, Kaiser F, von Rechenberg B, Scherf-Clavel O, Meinel L.ACS Biomater Sci Eng. 2023 Jun 12;9(6):2937-2948. doi: 10.1021/acsbiomaterials.2c00464
   

2022

  
   
45. Bone Concentration of Ampicillin/Sulbactam: A Pilot Study in Patients with Osteonecrosis of the Jaw.
Straub A, Stapf M, Fischer M, Vollmer A, Linz C, Lâm TT, Kübler A, Brands RC, Scherf-Clavel O, Hartmann S.
Int J Environ Res Public Health. 2022 Nov 13;19(22):14917. doi: 10.3390/ijerph192214917
44. Robustness of the honeybee neuro-muscular octopaminergic system in the face of cold stress.
Kaya-Zeeb S, Delac S, Wolf L, Marante AL, Scherf-Clavel O, Thamm M.
Front Physiol. 2022 Sep 27;13:1002740. doi: 10.3389/fphys.2022.1002740.
43. Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Short Communication.
Wohkittel C, Scherf-Clavel O, Fekete S, Romanos M, Högger P, Gerlach M.
Ther Drug Monit. 2022 Apr 1;44(2):340-344. doi: 10.1097/FTD.0000000000000917.
42. Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma.     
Isberner N., Gesierich A., Balakirouchenane D., Schilling B., Aghai-Trommeschlaeger F., Zimmermann S., Kurlbaum M., Puszkiel A., Blanchet B., Klinker H., Scherf-Clavel O.     
Cancers (2022) 14(19):4566, doi: 10.3390/cancers14194566
41. Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitoring.           
Aghai-Trommeschlaeger F., Zimmermann S., Gesierich A., Kalogirou C., Goebeler M.E., Jung P., Pelzer T., Kurlbaum M., Klinker H., Isberner N., Scherf-Clavel O.       
Clin Biochem. (2022) 105-106:35-43, doi: 10.1016/j.clinbiochem.2022.04.011
40. Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS. 
Opitz P., Zimmermann S., Mc Laughlin A.M., Müller L., Fuxius S., Illerhaus G., Scherf-Clavel O., Kloft C., Hempel G.; ON-TARGET study consortium.             
J Pharm Biomed Anal. (2022) 221:115033, doi: 10.1016/j.jpba.2022.115033
39. Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam.Straub A., Vollmer A., Lâm T.T., Brands R.C., Stapf M., Scherf-Clavel O., Bittrich M., Fuchs A., Kübler A.C., Hartmann S. Clin Oral Investig. (2022) 26:7033-7044 (2022), doi: 10.1007/s00784-022-04663-y.
38. A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients.
Gerner B, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Zimmermann S, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O.
Pharmaceutics. 2022 Nov 22;14(12):2556. doi: 10.3390/pharmaceutics14122556.
37. Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio.
Zimmermann S, Aghai F, Schilling B, Kraus S, Grigoleit GU, Kalogirou C, Goebeler ME, Jung P, Pelzer T, Klinker H, Isberner N, Scherf-Clavel O.
J Pharm Biomed Anal. 2022 Mar 20;211:114623. doi: 10.1016/j.jpba.2022.114623.
36. Targeted metabolic profiling of urinary steroids with a focus on analytical accuracy and sample stability.
Vogg N, Müller T, Floren A, Dandekar T, Scherf-Clavel O, Fassnacht M, Kroiss M, Kurlbaum M.
J Mass Spectrom Adv Clin Lab. 2022 Jul 25;25:44-52. doi: 10.1016/j.jmsacl.2022.07.006
35. Bile and excipient interactions directing drug pharmacokinetics in rats.
Schlauersbach J, Hanio S, Raschig M, Lenz B, Scherf-Clavel O, Meinel L.
Eur J Pharm Biopharm. 2022 Sep;178:65-68. doi: 10.1016/j.ejpb.2022.07.016.
34. Polymer selection impacts the pharmaceutical profile of site-specifically conjugated Interferon-α2a.
Hauptstein N, Pouyan P, Wittwer K, Cinar G, Scherf-Clavel O, Raschig M, Licha K, Lühmann T, Nischang I, Schubert US, Pfaller CK, Haag R, Meinel L.
J Control Release. 2022 Aug;348:881-892. doi: 10.1016/j.jconrel.2022.05.060
33. PEtOxylated Interferon-α2a Bioconjugates Addressing H1N1 Influenza A Virus Infection.
Hauptstein N, Dirauf M, Wittwer K, Cinar G, Siering O, Raschig M, Lühmann T, Scherf-Clavel O, Sawatsky B, Nischang I, Schubert US, Pfaller CK, Meinel L.
Biomacromolecules. 2022 Sep 12;23(9):3593-3601. doi: 10.1021/acs.biomac.2c00358
32. Drug-Drug Interactions With Over-The-Counter Medicines: Mind the Unprescribed.
Scherf-Clavel O.
Ther Drug Monit. 2022 Apr 1;44(2):253-274. doi: 10.1097/FTD.0000000000000924
31. Octopamine drives honeybee thermogenesis.
Kaya-Zeeb S, Engelmayer L, Straßburger M, Bayer J, Bähre H, Seifert R, Scherf-Clavel O, Thamm M.
Elife. 2022 Mar 15;11:e74334. doi: 10.7554/eLife.74334.
   

2021

  
   
30. Therapeutic drug monitoring of oral targeted antineoplastic drugs.
Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, Jaehde U, Steeghs N, Huitema ADR, Kloft C.
Eur J Clin Pharmacol. 2021 Apr;77(4):441-464. doi: 10.1007/s00228-020-03014-8.
29. The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.
Haider MS, Ahmad T, Groll J, Scherf-Clavel O, Kroiss M, Luxenhofer R.
Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):575-593. doi: 10.1007/s13318-021-00700-5.
28. Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis.
Sörgel F, Malin JJ, Hagmann H, Kinzig M, Bilal M, Eichenauer DA, Scherf-Clavel O, Simonis A, El Tabei L, Fuhr U, Rybniker J.
J Antimicrob Chemother. 2021 Feb 11;76(3):825-827. doi: 10.1093/jac/dkaa500.
27. Investigation of isomerization of dexibuprofen in a ball mill using chiral capillary electrophoresis.
Urlaub J, Kaiser RP, Scherf-Clavel O, Bolm C, Holzgrabe U.
Electrophoresis. 2021 Sep;42(17-18):1790-1799. doi: 10.1002/elps.202000307.
26. Simulation-Based Interpretation of Therapeutically Monitored Cabozantinib Plasma Concentration in Advanced Adrenocortical Carcinoma with Hemodialysis.
Zimmermann S, Kurlbaum M, Mayer S, Fassnacht M, Kroiss M, Scherf-Clavel O.
Ther Drug Monit. 2021 Oct 1;43(5):706-711. doi: 10.1097/FTD.0000000000000905.
25. The nitrosamine contamination of drugs, part 3: Quantification of 4-Methyl-1-nitrosopiperazine in rifampicin capsules by LC-MS/HRMS.
Wohlfart J, Scherf-Clavel O, Kinzig M, Sörgel F, Holzgrabe U.
J Pharm Biomed Anal. 2021 Sep 5;203:114205. doi: 10.1016/j.jpba.2021.114205.
24. Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
Mc Laughlin AM, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland SL, Huitema ADR, Steeghs N, Müller L, Fuxius S, Illerhaus G, Joerger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, For The On-Target Study Consortium.
Cancers (Basel). 2021 Dec 14;13(24):6281. doi: 10.3390/cancers13246281.
23. Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial.
Isberner N, Kraus S, Grigoleit GU, Aghai F, Kurlbaum M, Zimmermann S, Klinker H, Scherf-Clavel O.
Cancer Chemother Pharmacol. 2021 Dec;88(6):973-983. doi: 10.1007/s00280-021-04351-w.
22. Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug-Drug Interaction with Rifampin and Liver Impairment.
Gerner B, Scherf-Clavel O.
Pharmaceutics. 2021 May 22;13(6):778. doi: 10.3390/pharmaceutics13060778.
21. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
Aghai F, Zimmermann S, Kurlbaum M, Jung P, Pelzer T, Klinker H, Isberner N, Scherf-Clavel O.
Anal Bioanal Chem. 2021 Jan;413(2):599-612. doi: 10.1007/s00216-020-03031-7.
20. Therapeutic drug monitoring of oral targeted antineoplastic drugs.
Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, Jaehde U, Steeghs N, Huitema ADR, Kloft C.
Eur J Clin Pharmacol. 2021 Apr;77(4):441-464. doi: 10.1007/s00228-020-03014-8..
   

2020

  
   
19. Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib.
Kroiss M, Megerle F, Kurlbaum M, Zimmermann S, Wendler J, Jimenez C, Lapa C, Quinkler M, Scherf-Clavel O, Habra MA, Fassnacht M.
J Clin Endocrinol Metab. 2020 May 1;105(5):1461-8. doi: 10.1210/clinem/dgz318.
18. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
Aghai F, Zimmermann S, Kurlbaum M, Jung P, Pelzer T, Klinker H, Isberner N, Scherf-Clavel O.
Anal Bioanal Chem. 2021 Jan;413(2):599-612. doi: 10.1007/s00216-020-03031-7.
17. Constituents and Metabolites of a French Oak Wood Extract (Robuvit®) in Serum and Blood Cell Samples of Women Undergoing Hysterectomy.
Volpp L, Ferianec V, Ježovičová M, Ďuračková Z, Scherf-Clavel O, Högger P.
Front Pharmacol. 2020 Feb 26;11:74. doi: 10.3389/fphar.2020.00074.
   

2019

  
   
16. The contamination of valsartan and other sartans, part 1: New findings.
Sörgel F, Kinzig M, Abdel-Tawab M, Bidmon C, Schreiber A, Ermel S, Wohlfart J, Besa A, Scherf-Clavel O, Holzgrabe U.
J Pharm Biomed Anal. 2019 Aug 5;172:395-405. doi: 10.1016/j.jpba.2019.05.022.
15. A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin.
Trueck C, Hsin CH, Scherf-Clavel O, Schaeffeler E, Lenssen R, Gazzaz M, Gersie M, Taubert M, Quasdorff M, Schwab M, Kinzig M, Sörgel F, Stoffel MS, Fuhr U.
Clin Pharmacol Ther. 2019 Dec;106(6):1398-1407. doi: 10.1002/cpt.1564.
14. A HILIC-MS/MS assay for the quantification of metformin and sitagliptin in human plasma and urine: A tool for studying drug transporter perturbation.
Scherf-Clavel O, Kinzig M, Stoffel MS, Fuhr U, Sörgel F.
J Pharm Biomed Anal. 2019 Oct 25;175:112754. doi: 10.1016/j.jpba.2019.07.002.
13. The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities.
Scherf-Clavel O, Kinzig M, Besa A, Schreiber A, Bidmon C, Abdel-Tawab M, Wohlfart J, Sörgel F, Holzgrabe U.
J Pharm Biomed Anal. 2019 Aug 5;172:278-284. doi: 10.1016/j.jpba.2019.04.035.
12. Quantification of adefovir and pitavastatin in human plasma and urine by LC-MS/MS: A useful tool for drug-drug interaction studies.
Scherf-Clavel O, Kinzig M, Stoffel MS, Fuhr U, Sörgel F.
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 1;1125:121718. doi: 10.1016/j.jchromb.2019.121718.
11. A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring.
Friedl B, Kurlbaum M, Kroiss M, Fassnacht M, Scherf-Clavel O.
Anal Bioanal Chem. 2019 Jul;411(17):3951-3962. doi: 10.1007/s00216-019-01868-1.
10. Determination of hydroxybupropion in human serum for routine therapeutic drug monitoring in psychiatry: A tool for dose-individualization in treatment with bupropion.
Scherf-Clavel M, Wahl O, Menke A, Unterecker S.
Biomed Chromatogr. 2019 Oct;33(10):e4609. doi: 10.1002/bmc.4609. 
9. Development and validation of a new UHPLC method for related proteins in insulin and insulin analogues as an alternative to the European Pharmacopoeia RP-HPLC method.
Wahl O, Jorajuria S.
J Pharm Biomed Anal. 2019 Mar 20;166:71-82. doi: 10.1016/j.jpba.2018.12.034.
   

2018

  
   
8. Quantification of Hydrochlorothiazide and Ramipril/Ramiprilate in Blood Serum and Cerebrospinal Fluid: A Pharmacokinetic Assessment of Central Nervous System Adverse Effects.
Sigaroudi A, Kinzig M, Wahl O, Stelzer C, Schroeter M, Fuhr U, Holzgrabe U, Sörgel F.
Pharmacology. 2018;102(3-4):133-137. doi: 10.1159/000489999.
7. Impurity profiling of N,N'-ethylenebis-l-cysteine diethyl ester (Bicisate).
Wahl O, Cleynhens J, Verbruggen AM, Holzgrabe U.
J Pharm Biomed Anal. 2018 Feb 20;150:132-136. doi: 10.1016/j.jpba.2017.11.078.
6. Quantification of Bisoprolol and Metoprolol in Simultaneous Human Serum and Cerebrospinal Fluid Samples.
Sigaroudi A, Kinzig M, Wahl O, Stelzer C, Schroeter M, Fuhr U, Holzgrabe U, Sörgel F.
Pharmacology. 2018;101(1-2):29-34. doi: 10.1159/000480091.
   

2016

  
   
5. Amino acid analysis for pharmacopoeial purposes.
Wahl O, Holzgrabe U.
Talanta. 2016 Jul 1;154:150-63. doi: 10.1016/j.talanta.2016.03.071.
   

2015

  
   
4. Impurity profiling of ibandronate sodium by HPLC-CAD.
Wahl O, Holzgrabe U.
J Pharm Biomed Anal. 2015 Oct 10;114:254-64. doi: 10.1016/j.jpba.2015.06.002.
3. Evaluation of enantiomeric purity of magnesium-L-aspartate dihydrate.
Wahl O, Holzgrabe U.
J Pharm Biomed Anal. 2015 Jan;102:100-9. doi: 10.1016/j.jpba.2014.08.013.
   

2014

  
   
2. Impurity profiling of carbocisteine by HPLC-CAD, qNMR and UV/vis spectroscopy.
Wahl O, Holzgrabe U.
J Pharm Biomed Anal. 2014 Jul;95:1-10. doi: 10.1016/j.jpba.2014.02.012.
   

2011

  
   
1. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.
Wahl O, Oswald M, Tretzel L, Herres E, Arend J, Efferth T.
Curr Med Chem. 2011;18(21):3136-55. doi: 10.2174/092986711796391570.